Stifel Financial’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $642K | Sell |
3,721
-353
| -9% | -$65.4K | ﹤0.01% | 2712 |
|
|
2025
Q4 | $813K | Sell |
4,074
-1,871
| -31% | -$339K | ﹤0.01% | 2569 |
|
|
2025
Q3 | $930K | Buy |
5,945
+359
| +6% | +$57K | ﹤0.01% | 2434 |
|
|
2025
Q2 | $848K | Sell |
5,586
-79,603
| -93% | -$10.6M | ﹤0.01% | 2446 |
|
|
2025
Q1 | $12.8M | Sell |
85,189
-4,866
| -5% | -$816K | 0.01% | 745 |
|
|
2024
Q4 | $16.6M | Sell |
90,055
-10,538
| -10% | -$2.03M | 0.02% | 637 |
|
|
2024
Q3 | $19.8M | Sell |
100,593
-10,325
| -9% | -$2.15M | 0.02% | 586 |
|
|
2024
Q2 | $22.9M | Buy |
110,918
+1,372
| +1% | +$311K | 0.03% | 493 |
|
|
2024
Q1 | $29.7M | Buy |
109,546
+3,978
| +4% | +$950K | 0.03% | 424 |
|
|
2023
Q4 | $25M | Sell |
105,568
-527
| -0.5% | -$104K | 0.03% | 430 |
|
|
2023
Q3 | $20.8M | Buy |
106,095
+1,761
| +2% | +$362K | 0.03% | 451 |
|
|
2023
Q2 | $21.9M | Buy |
104,334
+6,704
| +7% | +$1.33M | 0.03% | 441 |
|
|
2023
Q1 | $19.7M | Buy |
97,630
+2,802
| +3% | +$635K | 0.03% | 460 |
|
|
2022
Q4 | $20.7M | Sell |
94,828
-5,137
| -5% | -$1.12M | 0.03% | 441 |
|
|
2022
Q3 | $19.7M | Buy |
99,965
+2,945
| +3% | +$636K | 0.03% | 434 |
|
|
2022
Q2 | $20.8M | Buy |
97,020
+1,910
| +2% | +$467K | 0.03% | 436 |
|
|
2022
Q1 | $27M | Buy |
95,110
+5,375
| +6% | +$1.66M | 0.04% | 403 |
|
|
2021
Q4 | $33.8M | Buy |
89,735
+3,804
| +4% | +$1.48M | 0.04% | 344 |
|
|
2021
Q3 | $35.5M | Buy |
85,931
+1,776
| +2% | +$738K | 0.05% | 307 |
|
|
2021
Q2 | $31.1M | Buy |
84,155
+12,079
| +17% | +$4.03M | 0.05% | 327 |
|
|
2021
Q1 | $20.9M | Buy |
72,076
+4,058
| +6% | +$1.13M | 0.03% | 426 |
|
|
2020
Q4 | $17M | Buy |
68,018
+6,838
| +11% | +$1.63M | 0.03% | 442 |
|
|
2020
Q3 | $13.9M | Buy |
61,180
+4,918
| +9% | +$1.02M | 0.03% | 438 |
|
|
2020
Q2 | $9.81M | Buy |
56,262
+5,115
| +10% | +$816K | 0.02% | 512 |
|
|
2020
Q1 | $6.44M | Buy |
51,147
+4,084
| +9% | +$613K | 0.02% | 587 |
|
|
2019
Q4 | $7.19M | Buy |
47,063
+2,950
| +7% | +$408K | 0.02% | 736 |
|
|
2019
Q3 | $5.85M | Buy |
44,113
+6,680
| +18% | +$896K | 0.01% | 773 |
|
|
2019
Q2 | $5.32M | Buy |
37,433
+11,952
| +47% | +$1.62M | 0.01% | 839 |
|
|
2019
Q1 | $3.69M | Buy |
25,481
+1,546
| +6% | +$203K | 0.01% | 949 |
|
|
2018
Q4 | $2.7M | Buy |
23,935
+1,316
| +6% | +$165K | 0.01% | 1016 |
|
|
2018
Q3 | $3.04M | Buy |
+22,619
| New | +$2.79M | 0.01% | 1049 |
|
|
2018
Q1 | – | Sell |
-2,086
| Closed | -$226K | – | 2711 |
|
|
2017
Q4 | $226K | Sell |
2,086
-97
| -4% | -$10.6K | ﹤0.01% | 2370 |
|
|
2017
Q3 | $233K | Sell |
2,183
-404
| -16% | -$41.5K | ﹤0.01% | 2290 |
|
|
2017
Q2 | $261K | Buy |
+2,587
| New | +$238K | ﹤0.01% | 2200 |
|
|
2014
Q4 | – | Sell |
-28,498
| Closed | -$1.7M | – | 2345 |
|
|
2014
Q3 | $1.7M | Sell |
28,498
-11,096
| -28% | -$635K | 0.01% | 828 |
|
|
2014
Q2 | $2.12M | Buy |
39,594
+1,250
| +3% | +$68.6K | 0.02% | 755 |
|
|
2014
Q1 | $2.31M | Buy |
+38,344
| New | +$2.24M | 0.02% | 699 |
|
Other funds holding CRL
VCM
VPM
Stifel Financial's CRL Position: Q1 2026 in Review
Stifel Financial reduced its Charles River Laboratories (CRL) stake by 8.7% in Q1 2026, selling an estimated $65.4K and leaving 3,721 shares worth $642K. The position accounts for ﹤0.01% of the portfolio, ranked #2712.
Stifel Financial first reported a position in CRL in Q1 2014 and has held it in 37 quarters since. The position peaked at $35.5M in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Stifel Financial held 3,721 shares of Charles River Laboratories worth $642K as of Q1 2026.
- Stifel Financial sold 353 Charles River Laboratories shares in Q1 2026, an estimated $65.4K.
- Charles River Laboratories made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #2712 holding.
- Stifel Financial first reported a position in Charles River Laboratories in Q1 2014 and has held it in 37 quarters since.
- Stifel Financial's Charles River Laboratories position peaked at $35.5M in Q3 2021.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.